John Greenman

Professor John Greenman

Professor of Tumour Immunology

Faculty and Department

  • Faculty of Health Sciences
  • School of Life Sciences

Summary

John is a tumour immunologist with extensive experience of developing lab on a chip technology for analysing tumour biopsies.

He has published over 150 peer-reviewed publications and his immunobiology group works closely with clinicians, chemists and engineers.

The majority of his research work has focused on tumours of the head and neck region, identifying novel markers of progression or treatment response.

1991-1995 Post-doctoral Research Fellow, Sir William Dunn School of Pathology, MRC Cellular Immunology Unit, University of Oxford

1995-1999 Lecturer in Immunology, Dept of Surgery, University of Hull

1999-2004 Senior Lecturer in Tumour Immunology, University of Hull

2004- 2009 Reader in Tumour Immunology, University of Hull

Currently a member of the NC3Rs David Sainsbury Fellowship Panel 2015 -

REF2014 - Appointed as Output Assessor for Panel UoA3 (2014)

Undergraduate

BSc programmes

- Clinical Microbiology and Immunology

- Professional and Research skills for Biomedical Sciences

- Reviews in Biomedical Science

- Final Year Research Projects, 20 and 40 credit

MSc programmes

- Tumour Immunology and Microenvironment

- Organ-specific Cancers: From Bench to Bedside

- Research Project and Dissertation

Journal Article

Low molecular weight heparin and direct oral anticoagulants influence tumour formation, growth, invasion and vascularisation by separate mechanisms

Featherby, S., Xiao, Y. P., Ettelaie, C., Nikitenko, L. L., Greenman, J., & Maraveyas, A. (2019). Low molecular weight heparin and direct oral anticoagulants influence tumour formation, growth, invasion and vascularisation by separate mechanisms. Scientific reports, 9(1), https://doi.org/10.1038/s41598-019-42738-1

The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart

Onwuli, D. O., Samuel, S., Sfyri, P., Welham, K., Goddard, M., Abu-Omar, Y., …Beltran-Alvarez, P. (2019). The inhibitory subunit of cardiac troponin (cTnI) is modified by arginine methylation in the human heart. International journal of cardiology, 282, 76-80. https://doi.org/10.1016/j.ijcard.2019.01.102

A patient tumour-on-a-chip system for personalised investigation of radiotherapy based treatment regimens

Kennedy, R., Kuvshinov, D., Sdrolia, A., Kuvshinova, E., Hilton, K., Crank, S., …Greenman, J. (2019). A patient tumour-on-a-chip system for personalised investigation of radiotherapy based treatment regimens. Scientific reports, 9(1), https://doi.org/10.1038/s41598-019-42745-2

A novel microfluidic device capable of maintaining functional thyroid carcinoma

Riley, A., Green, V., Cheah, R., McKenzie, G., Karsai, L., England, J., & Greenman, J. (2019). A novel microfluidic device capable of maintaining functional thyroid carcinoma. BMC Cancer, 19, https://doi.org/10.1186/s12885-019-5465-z

Inhibiting arginine methylation as a tool to investigate cross-talk with methylation and acetylation post-translational modifications in a glioblastoma cell line

Samuel, S. F., Marsden, A. J., Deepak, S., Rivero, F., Greenman, J., & Beltran-Alvarez, P. (2018). Inhibiting arginine methylation as a tool to investigate cross-talk with methylation and acetylation post-translational modifications in a glioblastoma cell line. Proteomes, 6(4), https://doi.org/10.3390/proteomes6040044

Research interests

Coming from an immunology background, Professor Greenman is extremely interested in understanding how the immune system is often subverted during carcinogenesis, and more importantly how such knowledge can be used clinically (diagnostically, prognostically or therapeutically).

Current and recent grants

H2020-MSCA-RISE-2016, €976,000 (€153k to Hull) (Greenman). Blood test for clinical therapy guidance of non-small cell lung cancer patients.

Yorkshire Cancer Research, €99,198 (Lind and Greenman). Peripheral blood detection of EGFR status in lung cancer patients. 01/11/2016 - 31/10/2018

Innovate UK/EPSRC €496,000 (€193k to Hull) (Greenman, Green, Cawthorne). Development of a multi-purpose small animal phantom for pre-clinical radiotherapy studies. 01/03/2016 - 28/02/2018.

Yorkshire Cancer Research €123,312 (Archibald, Madden & Greenman). Chemokine receptor targeted therapies. 01/02/2014 - 31/01/2016.

British Lung Foundation €24,800 (Loveday, Lind, Haswell & Greenman). Development of microfluidic device for response to chemotherapy in malignant mesothelioma. 01/10/2013 - 30/09/2015.

Technology Strategy Board Sepsis I: Multi-pathogen detection and/or simple discrimination €399,000 (Greenman, Dyer, Haswell, BioGene Ltd). Rapid, on-chip, multiplexed detection of sepsis-causing organisms from blood samples. 01/09/2012 - 31/08/2015.

FP7-SME-2012. Point-of-care blood device for fast and reliable prediction of drug response in non-small cell lung carcinoma patients from blood samples (LungCARD 315586) University of Hull (Haswell & Greenman); Hull and East Riding NHS Trust (Lind & Greenman) (€306,000 to Hull; 1.2M Euro total) 01/01/2013 - 28/2/2014.

NC3R €450,000 (Greenman, Madden, Flynn, Haswell, Maraveyas). Replacement of animal models for tumour biology with a multifunctional microfluidic-based approach. 01/10/2011 - 30/09/2014.

NIHR (i4i programme). €667,542 (Elliott, Wadhawan, Singh, MacFie, Greenman). Development of a placement sensing nasogastric tube. 01/07/2011 - 30/06/2014.

Hull and East Riding Cardiac Trust. €76,128 (Greenman, Jones, Dyer, Wadhawan, Haswell, Griffin, Seymour) Integrated microfluidic devices for real-time measurement of biochemical changes in heart tissue. 01/03/2011 - 30/11/2012.

Heart Research UK €199,728 (Greenman, Haswell and Seymour). Development of microfluidic devices for analysis of function in normal and diseased cardiac tissue. 10/2007 - 09/2011.

EPSRC EP/H007385 €210,949 (Haswell & Greenman). Commercialisation of lab-on-a-chip technology for DNA profiling. 08/2009 - 07/2010.

Postgraduate supervision

I welcome applications to work with me in either the biomedical applications of microfluidic devices or head and neck immunobiology. These can come from basic scientists or medically trained individuals.

Completed PhDs

60 postgraduate (PhD and MD) students successfully supervised since 1999.

PhDCheah, R. (2016), Monitoring the Response of Head and Neck Tumour Tissue to Irradiation Using a Microfluidic-Based Approach

Smith, J. (2016), The Effect of HNSCC-derived Soluble Factors on the Proliferation and Function of Immune Cells

Chandrabalan, K. (2016), A Microfluidic Approach to the Study of Cellular Responses to Oxidative Stress

Williamson, J. (2016), The Role of Endothelial Adhesins in Leukocyte Adhesion in Response to Pharmaceutical Agents that Induce Pulmonary Fibrosis

Todd, A. (2016), Role of Hypoxia-Induced Adam 10 in Colorectal Cancer Progression

Pacelli, A. (2015), Development of a Pet Probe for the Imaging of Cox-2 Expression in Cancers

MDPatel, R. (2016), An Observational Pilot Study to Assess the Potential of a Microfluidic Tissue Culture Model to Predict Rectal Cancer Response to Neo-Adjuvant Therapy

Zahoor, T. (2016), Does HPV-16 Seropositivity Correlate with T-cell Distribution Providing Additional Prognostic Information in Infected HNSCC Patients?

Carr, S. (2013), Assessing the Effects of Radiotherapy on Head and Neck Squamous Cell Carcinoma using Microfluidic Techniques

Current PhD supervisors

Currently acting as primary and secondary supervisor to 18 postgraduate students covering all aspects of my research interests (three are currently writing up).